Inclusive of all taxes
1 Vial(s) Of 10ml
Mabtas 100mg Injection, containing the active ingredient rituximab, is used to treat various conditions in adults and some children. These include non-Hodgkin lymphoma, chronic lymphocytic leukemia (both cancers affecting B-lymphocytes), moderate to severe rheumatoid arthritis (in combination with methotrexate), granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris a rare autoimmune disease causing painful blisters on the skin and mucous membranes.
Mabtas 100mg Injection is an anti-CD20 monoclonal antibody administered intravenously under the supervision of a qualified healthcare professional. The dosage regimen and duration of therapy are determined by the prescribing physician based on the patient’s clinical condition. Strict adherence to medical guidance is essential, as improper use or premature discontinuation may lead to adverse outcomes. Clinical benefits may take several weeks to months to become evident.
Common side effects of Mabtas include headache, weakness, dizziness, swelling, infections, diarrhea, itchy skin, hair loss, and changes in blood pressure. The medicine can lower red and white blood cell counts, raising the risk of infections. Severe infusion-related reactions such as chest pain, difficulty breathing, vomiting, skin rashes, or throat swelling may occur during or within 24 hours of administration and require immediate medical attention.
Before starting treatment, inform your doctor if you have heart or liver disease, breathing problems, a history of hepatitis B, or are on any other medications. Mabtas is not recommended during pregnancy or breastfeeding. Effective contraception must be used during treatment and for at least 12 months after the last dose to avoid pregnancy. Regular blood tests are necessary to monitor blood cell levels and liver function throughout therapy.
Rituximab is used to treat non-Hodgkin lymphoma, a cancer that affects B-lymphocytes, which are a type of white blood cell involved in the immune response.
It is also prescribed for chronic lymphocytic leukemia, the most common type of leukemia in adults, where abnormal B-cells grow uncontrollably.
Rituximab is used in combination with methotrexate to treat moderate to severe rheumatoid arthritis in adults who have not responded adequately to other disease-modifying antirheumatic drugs (DMARDs).
This medication helps manage granulomatosis with polyangiitis, a rare autoimmune condition that causes inflammation of the blood vessels, especially in the lungs, kidneys, and sinuses.
Rituximab is also effective in treating microscopic polyangiitis, another autoimmune disorder that causes small blood vessel inflammation and can affect multiple organs.
It is used in the treatment of pemphigus vulgaris, a rare and serious autoimmune disease that leads to blistering of the skin and mucous membranes.
Mabtas 100mg Injection contains rituximab, a chimeric monoclonal antibody that specifically targets the CD20 antigen found on the surface of B-lymphocytes (a type of white blood cell involved in immune responses and certain cancers). Rituximab binds to the CD20 antigen and causes the destruction of these B-cells through several mechanisms:
Mabtas(rituximab) works through Antibody-Dependent Cellular Cytotoxicity (ADCC), where the immune system recognizes rituximab-coated B-cells as harmful and destroys them using natural killer (NK) cells and other immune cells.
It also acts through Complement-Dependent Cytotoxicity (CDC) by activating the complement system, which breaks down and eliminates the rituximab-tagged B-cells from the body.
Additionally, rituximab can trigger apoptosis, or programmed cell death, causing B-cells to self-destruct. By targeting abnormal or overactive B-cells, Mabtas helps treat cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune diseases such as rheumatoid arthritis.
Side Effects of Mabtas 100mg Injection
Like all medications, Mabtas 100mg Injection may cause side effects. However, not everyone will experience them.
Serious Side Effects (Seek immediate medical attention):
Common Side Effects (Usually mild and temporary):
Mabtas 100mg Injection is administered as an intravenous infusion under the supervision of a qualified healthcare professional. The dosage and treatment schedule vary depending on the indication, patient’s body surface area, and clinical condition. It may be used alone or in combination with chemotherapy for cancers such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, or in defined regimens for autoimmune disorders like rheumatoid arthritis. The exact dosage and duration are determined by the prescribing physician.
Mabtas 100mg Injection (rituximab) is not recommended during breastfeeding. Rituximab may pass into breast milk and could harm the nursing infant. Breastfeeding should be avoided during treatment and for at least 6 months after the last dose. Patients are advised to consult their physician for further guidance before resuming breastfeeding.
There is no clear evidence on the interaction between rituximab and alcohol. However, patients are advised to consult their doctor before consuming alcohol during treatment.
Mabtas 100mg Injection may rarely cause serious lung problems, including pneumonitis or breathing difficulties. Patients with lung conditions should use it cautiously and report symptoms like cough, shortness of breath, or chest tightness to their doctor immediately.
Mabtas 100mg Injection may cause fatigue, dizziness, or other side effects that can affect alertness. Patients should avoid driving or operating machinery if they experience these symptoms.
Mabtas 100mg Injection should be avoided during pregnancy unless clearly needed. Rituximab may harm the unborn baby. Women of childbearing potential should use effective contraception during treatment and for 12 months after the last dose.
Mabtas is used to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris.
It is given as an intravenous (IV) infusion by a healthcare professional in a hospital or clinical setting.
No, Mabtas should not be used if you have an active or serious infection. Inform your doctor before starting the treatment.
Common side effects include headache, weakness, fever, rash, diarrhea, dizziness, swelling, and infections.
Yes, serious risks include severe infusion reactions, hepatitis B reactivation, low blood cell counts, and severe infections. Inform your doctor immediately if you experience unusual symptoms.
Live vaccines should be avoided during and after treatment, as your immune response may be weakened.
No, Mabtas is not recommended during pregnancy or breastfeeding. Use effective contraception during treatment and for 12 months after the last dose.
The response to treatment may vary depending on the condition. It may take several weeks or months to notice improvement.
Yes, regular blood tests are required to monitor blood cell counts, liver function, and screen for infections like hepatitis B.
No, you should not stop treatment without consulting your doctor, even if you feel better. Sudden discontinuation may worsen your condition.
| Active ingredient | Rituximab |
| Pharmacologic class | Anti-CD20 monoclonal antibodies |
| Medication category | Antineoplastics Agent,(DMARDs) Disease-Modifying Antirheumatic Drugs. |
| Dosage forms | Injection |
Azadine 100mg Injection contains Azacitidine which belongs to the group of medicines called Anticancer agents. It is used in adults to treat all sub-types of myelodysplastic syndromes (MDS; group of cancers associated with blood and bone marrow) and certain types of blood cancers known as Chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
Azadine 100mg Injection is typically used in adults who cannot undergo stem cell transplantation. It may be also used to treat other conditions, as determined by the doctor.
Azadine Injection is given as an injection under the medical supervision of a doctor. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised.
You must inform your doctor before taking any vaccination while on treatment with this medicine. Regular blood tests are required to check your blood cells along with the heart, liver, and kidney.
Before taking it, tell your doctor if you have liver, or kidney problems or are taking any medicines to treat infections. Many other medicines can affect, or be affected by, this medicine so let your doctor know all medications you are using.
Azadine 100mg Injection is an anticancer medication. It works by blocking the actions of certain enzymes (DNA/RNA methyltransferase) within the cancer cells that is required for the cells to grow and multiply. It also reduces the production of new genetic material (RNA and DNA) within the cells. As a result, it prevents abnormal cell division within the body, slows down the growth of cancer cells and helps the bone marrow to produce normal blood cells.
It is used to treat:
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Ques 1: What is the use of AZADINE 100MG INJECTION?
Ans :AZADINE 100MG INJECTION is used in adults to treat all sub-types of myelodysplastic syndromes (MDS; group of cancers associated with blood and bone marrow) and certain types of blood cancers known as Chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
Ques 2: How does AZADINE 100MG INJECTION works?
Ans :AZADINE 100MG INJECTION is an anticancer medication. It works by blocking the actions of certain enzymes (DNA/RNA methyltransferase) within the cancer cells that is required for the cells to grow and multiply. It also reduces the production of new genetic material (RNA and DNA) within the cells. As a result, it prevents abnormal cell division within the body, slows down the growth of cancer cells and helps the bone marrow to produce normal blood cells.
Ques 3: Can I take AZADINE 100MG INJECTION during breastfeeding?
Ans :No. AZADINE 100MG INJECTION is not recommended for use in breast-feeding women. Therefore, inform your doctor before receiving it.
Ques 4: Can AZADINE 100MG INJECTION increase the risk of infections?
Ans :AZADINE 100MG INJECTION may cause a drop in the number of white blood cells in the body and may weaken your immune system. As a result, you may be at a greater risk of getting infected while receiving AZADINE 100MG INJECTION. To avoid this, your doctor will regular monitor your blood counts as a precaution. However, inform your doctor if you experience any signs of infection such as fever.
Ques 5: Can the use of AZADINE 100MG INJECTION make me feel tired?
Ans :Yes. AZADINE 100MG INJECTION may make you feel tired easily. This is because, it reduces the levels of red blood cells in your blood and may make you anemic. Consult your doctor if you experience tiredness after receiving AZADINE 100MG INJECTION. Tiredness can also occur if you have any pre-existing disease conditions such as liver or kidney impairment while receiving this medicine.
Ques 6: Can I drive a car after receiving AZADINE 100MG INJECTION?
Ans :AZADINE 100MG INJECTION may make you feel tired or weak. Therefore, do not drive or operate any heavy tools or machines if your ability is affected by AZADINE 100MG INJECTION.
Ques 7: How AZADINE 100MG INJECTION is administered?
Ans :AZADINE 100MG INJECTION will be given to you only by a doctor or a nurse beneath the skin (subcutaneously) of thighs, arms or abdomen.
Ques 8: How to control nausea caused due to AZADINE 100MG INJECTION?
Ans :Generally, anticancer medicines are associated with uncontrollable nausea and vomiting. To avoid this, your doctor would prescribe a suitable medicine to control them along with AZADINE 100MG INJECTION. If not, consult your doctor for a suitable anti-emetic medicine. Do not self-treat nausea.
Mabtas 100mg Injection, containing the active ingredient rituximab, is used to treat various conditions in adults and some children. These include non-Hodgkin lymphoma, chronic lymphocytic leukemia (both cancers affecting B-lymphocytes), moderate to severe rheumatoid arthritis (in combination with methotrexate), granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris a rare autoimmune disease causing painful blisters on the skin and mucous membranes.
Mabtas 100mg Injection is an anti-CD20 monoclonal antibody administered intravenously under the supervision of a qualified healthcare professional. The dosage regimen and duration of therapy are determined by the prescribing physician based on the patient’s clinical condition. Strict adherence to medical guidance is essential, as improper use or premature discontinuation may lead to adverse outcomes. Clinical benefits may take several weeks to months to become evident.
Common side effects of Mabtas include headache, weakness, dizziness, swelling, infections, diarrhea, itchy skin, hair loss, and changes in blood pressure. The medicine can lower red and white blood cell counts, raising the risk of infections. Severe infusion-related reactions such as chest pain, difficulty breathing, vomiting, skin rashes, or throat swelling may occur during or within 24 hours of administration and require immediate medical attention.
Before starting treatment, inform your doctor if you have heart or liver disease, breathing problems, a history of hepatitis B, or are on any other medications. Mabtas is not recommended during pregnancy or breastfeeding. Effective contraception must be used during treatment and for at least 12 months after the last dose to avoid pregnancy. Regular blood tests are necessary to monitor blood cell levels and liver function throughout therapy.
Rituximab is used to treat non-Hodgkin lymphoma, a cancer that affects B-lymphocytes, which are a type of white blood cell involved in the immune response.
It is also prescribed for chronic lymphocytic leukemia, the most common type of leukemia in adults, where abnormal B-cells grow uncontrollably.
Rituximab is used in combination with methotrexate to treat moderate to severe rheumatoid arthritis in adults who have not responded adequately to other disease-modifying antirheumatic drugs (DMARDs).
This medication helps manage granulomatosis with polyangiitis, a rare autoimmune condition that causes inflammation of the blood vessels, especially in the lungs, kidneys, and sinuses.
Rituximab is also effective in treating microscopic polyangiitis, another autoimmune disorder that causes small blood vessel inflammation and can affect multiple organs.
It is used in the treatment of pemphigus vulgaris, a rare and serious autoimmune disease that leads to blistering of the skin and mucous membranes.
Mabtas 100mg Injection contains rituximab, a chimeric monoclonal antibody that specifically targets the CD20 antigen found on the surface of B-lymphocytes (a type of white blood cell involved in immune responses and certain cancers). Rituximab binds to the CD20 antigen and causes the destruction of these B-cells through several mechanisms:
Mabtas(rituximab) works through Antibody-Dependent Cellular Cytotoxicity (ADCC), where the immune system recognizes rituximab-coated B-cells as harmful and destroys them using natural killer (NK) cells and other immune cells.
It also acts through Complement-Dependent Cytotoxicity (CDC) by activating the complement system, which breaks down and eliminates the rituximab-tagged B-cells from the body.
Additionally, rituximab can trigger apoptosis, or programmed cell death, causing B-cells to self-destruct. By targeting abnormal or overactive B-cells, Mabtas helps treat cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune diseases such as rheumatoid arthritis.
Side Effects of Mabtas 100mg Injection
Like all medications, Mabtas 100mg Injection may cause side effects. However, not everyone will experience them.
Serious Side Effects (Seek immediate medical attention):
Common Side Effects (Usually mild and temporary):
Mabtas 100mg Injection is administered as an intravenous infusion under the supervision of a qualified healthcare professional. The dosage and treatment schedule vary depending on the indication, patient’s body surface area, and clinical condition. It may be used alone or in combination with chemotherapy for cancers such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, or in defined regimens for autoimmune disorders like rheumatoid arthritis. The exact dosage and duration are determined by the prescribing physician.
Mabtas 100mg Injection (rituximab) is not recommended during breastfeeding. Rituximab may pass into breast milk and could harm the nursing infant. Breastfeeding should be avoided during treatment and for at least 6 months after the last dose. Patients are advised to consult their physician for further guidance before resuming breastfeeding.
There is no clear evidence on the interaction between rituximab and alcohol. However, patients are advised to consult their doctor before consuming alcohol during treatment.
Mabtas 100mg Injection may rarely cause serious lung problems, including pneumonitis or breathing difficulties. Patients with lung conditions should use it cautiously and report symptoms like cough, shortness of breath, or chest tightness to their doctor immediately.
Mabtas 100mg Injection may cause fatigue, dizziness, or other side effects that can affect alertness. Patients should avoid driving or operating machinery if they experience these symptoms.
Mabtas 100mg Injection should be avoided during pregnancy unless clearly needed. Rituximab may harm the unborn baby. Women of childbearing potential should use effective contraception during treatment and for 12 months after the last dose.
Mabtas is used to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris.
It is given as an intravenous (IV) infusion by a healthcare professional in a hospital or clinical setting.
No, Mabtas should not be used if you have an active or serious infection. Inform your doctor before starting the treatment.
Common side effects include headache, weakness, fever, rash, diarrhea, dizziness, swelling, and infections.
Yes, serious risks include severe infusion reactions, hepatitis B reactivation, low blood cell counts, and severe infections. Inform your doctor immediately if you experience unusual symptoms.
Live vaccines should be avoided during and after treatment, as your immune response may be weakened.
No, Mabtas is not recommended during pregnancy or breastfeeding. Use effective contraception during treatment and for 12 months after the last dose.
The response to treatment may vary depending on the condition. It may take several weeks or months to notice improvement.
Yes, regular blood tests are required to monitor blood cell counts, liver function, and screen for infections like hepatitis B.
No, you should not stop treatment without consulting your doctor, even if you feel better. Sudden discontinuation may worsen your condition.
| Active ingredient | Rituximab |
| Pharmacologic class | Anti-CD20 monoclonal antibodies |
| Medication category | Antineoplastics Agent,(DMARDs) Disease-Modifying Antirheumatic Drugs. |
| Dosage forms | Injection |
Life-Saving Medicines Expert
Affordable Patient-Centered Care
Authentic, Top-Quality Medicines
Careful & Timely Medicine Deliveries
Login with Facebook
Login with Google
